Se connecter

Bibliographies thématiques / Implantable Drug Delivery System (IDDS) / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Implantable Drug Delivery System (IDDS).

Articles de revues sur le sujet « Implantable Drug Delivery System (IDDS) »

Auteur : Grafiati

Publié le 7 juin 2025

Mis à jour le 2 août 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Implantable Drug Delivery System (IDDS) ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Yogita, Pawar* Shubhangi doer Priti Kolte Nitin kale. "Implantable Drug Delivery System." International Journal of Pharmaceutical Sciences 2, no. 8 (2024): 3684–88. https://doi.org/10.5281/zenodo.13369182.

Texte intégral

Résumé :

Implantable drug delivery system [IDDs] in modern medicine may traced to Deans by and Parkes who in 1938. The oral route is popular and convenient means of drug delivery . with there advantage there is also challenges. many drug are not suitable for the oral route of administration such as insulin. this article gives an overview of classification of these drug delivery devices ;the mechanism of drug release ;the materials used for manufacture. Implants are small sterile solid masses consisting of highly purified drug made by compression or molding or extrusion. Implants are developed with a vi

Styles APA, Harvard, Vancouver, ISO, etc.

2

Swetha, Dr M., Makka Vandana, Mandugula Shiva Nandini, and Manumari Vaishnavi. "Implantable Drug Delivery System." International Journal of Multidisciplinary Research and Growth Evaluation 6, no. 1 (2025): 1578–82. https://doi.org/10.54660/.ijmrge.2025.6.1.1578-1582.

Texte intégral

Résumé :

Implantable drug delivery systems [IDDS] provide a viable substitute for conventional medication delivery techniques. The most popular medication delivery methods, oral and injectable, frequently cause blood drug concentrations to peak and then fall. This calls for ongoing administration in order to sustain therapeutic medication levels. Oral medication distribution also has to contend with issues such first-pass metabolism and drug degradation in the gastrointestinal system. Conversely, IDDS allow for prolonged medication release, which makes them particularly useful for treating chronic illn

Styles APA, Harvard, Vancouver, ISO, etc.

3

Vaishnavi S. Mukhmale, Sakshi Y. Patrikar, Nandkishor B. Deshmukh, and Swati P. Deshmukh. "Implantable drug delivery systems: An overviews." GSC Advanced Research and Reviews 22, no. 1 (2025): 123–32. https://doi.org/10.30574/gscarr.2025.22.1.0002.

Texte intégral

Résumé :

Implant are sterile solid mass that contains medicine, prepared by different ways like extrusion, moulding or contraction. The conventional routes of medicine administration has limited control over medicine release and maintaining constant tube remedial medicine attention for longer ages of time. To avoid these problems associated with application of traditional lozenge forms, there was essential need for development of new lozenge forms which would discharge medicines at controlled rate for original exertion. This led to enhancement of Novel Drug Delivery Systems (NDDS) that offers optimisat

Styles APA, Harvard, Vancouver, ISO, etc.

4

Haider, Rehan. "Implanted Drug Delivery System for Control of Chronic Pain." New Medical Innovations and Research 6, no. 3 (2025): 01–10. https://doi.org/10.31579/2767-7370/147.

Texte intégral

Résumé :

Implanted drug delivery system {IDDS} have emerged as a promising strategy for managing chronic pain, offering precise and sustained drug administration to achieve optimal pain relief while minimizing adverse effects. This abstract reviews the key aspects of IDDS in the context of chronic pain control. Chronic pain, characterized by its persistence over extended periods, presents a significant challenge in medical practice due to its complex and multifaceted nature. Traditional oral medication often fall short of providing consistent pain relief while avoiding systemic side effects. IDDS addre

Styles APA, Harvard, Vancouver, ISO, etc.

5

Stearns, L. J., W. H. Poling, J. Kiser, J. Nasternak, and E. Berryman. "Pancreatic cancer survivorship: Intrathecal drug delivery system for pain management." Journal of Clinical Oncology 24, no. 18_suppl (2006): 14100. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14100.

Texte intégral

Résumé :

14100 Background: Pancreatic cancer is predominantly unresectable at diagnosis and is most frequently fatal. Nationally the average survivorship is 10 months. Among pancreatic cancer patients, pain is associated with decreased survival rates. Quality of life and survivorship are the principal outcome measures for these patients. Successful pain management may be a significant predictor of prolonged survivorship. No study has demonstrated an impact on survivorship secondary to the treatment of pancreatic cancer pain and the use of Intrathecal Drug Delivery Systems (IDDS). Methods: A retrospecti

Styles APA, Harvard, Vancouver, ISO, etc.

6

Amreen, Soha, S. M. Shahidulla, Aasia Sultana, and Nimrah Fatima. "Implantable Drug Delivery System: An Innovative Approach." Journal of Drug Delivery and Therapeutics 13, no. 5 (2023): 98–105. http://dx.doi.org/10.22270/jddt.v13i5.6069.

Texte intégral

Résumé :

The conventional routes of drug administration has limited control over drug release and maintaining constant plasma therapeutic drug concentrations for longer periods of time. To avoid these problems associated with utilization of traditional dosage forms, there was essential need for development of new dosage forms which would discharge drugs at controlled rate for local activity. This led to improvement of Novel Drug Delivery Systems (NDDS) that offers optimisation of therapeutic properties of drugs and makes them safer, productive and dependable over traditional ways of administration. Imp

Styles APA, Harvard, Vancouver, ISO, etc.

7

Smith, Thomas J., Peter S. Staats, Timothy Deer, et al. "Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and Survival." Journal of Clinical Oncology 20, no. 19 (2002): 4040–49. http://dx.doi.org/10.1200/jco.2002.02.118.

Texte intégral

Résumé :

PURPOSE: Implantable intrathecal drug delivery systems (IDDSs) have been used to manage refractory cancer pain, but there are no randomized clinical trial (RCT) data comparing them with comprehensive medical management (CMM). PATIENTS AND METHODS: We enrolled 202 patients on an RCT of CMM versus IDDS plus CMM. Entry criteria included unrelieved pain (visual analog scale [VAS] pain scores ≥ 5 on a 0 to 10 scale). Clinical success was defined as ≥ 20% reduction in VAS scores, or equal scores with ≥ 20% reduction in toxicity. The main outcome measure was pain control combined with change of toxic

Styles APA, Harvard, Vancouver, ISO, etc.

8

Tanisha, Bhagria *Anjali, and Duggal Sanjiv. "IMPLANTATIONS: REVOLUTIONIZING DRUG DELIVERY FOR IMPROVED PATIENT OUTCOMES." World Journal of Pharmaceutical Science and Research 4, no. 2 (2025): 1027–41. https://doi.org/10.5281/zenodo.15356074.

Texte intégral

Résumé :

The oral route of administration is the most popular and convenient route of drug delivery. However, despite its advantages, it also has limitations. There are many drugs that are not suitable for oral route of administration due to their first pass metabolism, ideal characteristics and adverse effects of the treatment. Moreover, the effectiveness of oral delivery depends significantly on patient adherence. Implantable drug delivery devices (IDDS) are an alternative system that can achieve effective delivery of drug with appropriate concentrations. As a result, it reduces the systemic side-eff

Styles APA, Harvard, Vancouver, ISO, etc.

9

Goel, Vasudha, Melissa Ann Geller, Anne Hudson Blaes, and Amitabh Gulati. "Intrathecal drug delivery systems for cancer pain control: Insights on current contemporary practices in the US." Journal of Clinical Oncology 41, no. 16_suppl (2023): 6605. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6605.

Texte intégral

Résumé :

6605 Background: About a third of cancer survivors report moderate to severe pain. Intrathecal drug delivery system (IDDS) is an implantable pain control option for treating intractable chronic pain not responsive to systemic opioid therapy. Studies on the current practices in the US around the utilization of IDDS for cancer pain are lacking. Methods: The Nationwide inpatient sample (NIS) dataset is funded by the Agency for healthcare research and quality (AHRQ) for multistate healthcare research & decision-making. Adult patients admitted to hospitals with a primary or secondary cancer dia

Styles APA, Harvard, Vancouver, ISO, etc.

10

Han, Xiao-Le, Tao Zhou, Jian-Ming Xu, Shu-Feng Zhang, Ye-Zhou Hu, and Yi Liu. "Integrated Perspective on Functional Organic Electrochemical Transistors and Biosensors in Implantable Drug Delivery Systems." Chemosensors 13, no. 6 (2025): 215. https://doi.org/10.3390/chemosensors13060215.

Texte intégral

Résumé :

Although traditional drug delivery methods are widely used in clinical practice, their inherent limitations often compromise therapeutic efficacy. Therefore, the development of more precise and efficient drug delivery systems is essential to enhance treatment outcomes and reduce adverse effects. Implantable drug delivery systems (IDDSs) represent intelligent platforms capable of autonomously regulating drug release in response to a patient’s physiological state. By enabling controlled release and personalized dosing, IDDSs have been widely applied in the management of chronic conditions such a

Styles APA, Harvard, Vancouver, ISO, etc.

11

Fayzullin, Alexey, Alesia Bakulina, Karen Mikaelyan, Anatoly Shekhter, and Anna Guller. "Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape." Bioengineering 8, no. 12 (2021): 205. http://dx.doi.org/10.3390/bioengineering8120205.

Texte intégral

Résumé :

Precise delivery of therapeutics to the target structures is essential for treatment efficiency and safety. Drug administration via conventional routes requires overcoming multiple transport barriers to achieve and maintain the local drug concentration and commonly results in unwanted off-target effects. Patients’ compliance with the treatment schedule remains another challenge. Implantable drug delivery systems (IDDSs) provide a way to solve these problems. IDDSs are bioengineering devices surgically placed inside the patient’s tissues to avoid first-pass metabolism and reduce the systemic to

Styles APA, Harvard, Vancouver, ISO, etc.

12

Koyyalagunta, Dhanalakshmi. "Lumbar Subarachnoid Hematoma Following an Epidural Blood Patch for Meningeal Puncture Headache Related to the Implantation of an Intrathecal Drug Delivery System." Pain Physician 3;17, no. 3;5 (2014): E405—E411. http://dx.doi.org/10.36076/ppj.2014/17/e405.

Texte intégral

Résumé :

Persistent meningeal puncture headache (MPH) is a known complication following both intentional and unintentional puncture of the dura mater. We present a case of persistent MPH following implantation of an intrathecal drug delivery system (IDDS). Two separate epidural blood patches (EBP) were performed under radiographic guidance with contrast visualization of the epidural space on postoperative days 16 and 28, respectively. The case was complicated by the development of a symptomatic lumbar subarachnoid hematoma diagnosed on postoperative day 35. The patient subsequently underwent a laminect

Styles APA, Harvard, Vancouver, ISO, etc.

13

Zhou, Gang, Yu Bao Li, and Soo Wohn Lee. "Preparation of the Nano-Hydroxyapatite/Chitosan/Konjac Glucomannan Composite as a Novel Degradable Drug Delivery System." Materials Science Forum 569 (January 2008): 357–60. http://dx.doi.org/10.4028/www.scientific.net/msf.569.357.

Texte intégral

Résumé :

Nano-hydroxyapatite (n-HA)/chitosan (CS)/konjac glucomannan (KGM) composite was prepared by integrating composition and molding. Then, X-ray diffraction (XRD) and scanning electron microscopy (SEM) were used to analyze the physical, chemical and degradable properties of the composite before and after in simulated body fluid (SBF). Moreover, study in vitro test for drug delivery revealed that the amount of released pentoxifylline (1-[5-oxohexyl]-3,7-dimethylxanthine)(PTX) reached a plateau and equaled 80% of the drug loaded in an implant. The newly develop n-HA/CS/KGM composite may serve as a g

Styles APA, Harvard, Vancouver, ISO, etc.

14

Konrad, Peter E., John M. Huffman, Lisa M. Stearns, et al. "Intrathecal Drug Delivery Systems (IDDS): The Implantable Systems Performance Registry (ISPR)." Neuromodulation: Technology at the Neural Interface 19, no. 8 (2016): 848–56. http://dx.doi.org/10.1111/ner.12524.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Mostafa, Mahmoud, Adel Al Fatease, Raid G. Alany, and Hamdy Abdelkader. "Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases." Pharmaceutics 15, no. 6 (2023): 1746. http://dx.doi.org/10.3390/pharmaceutics15061746.

Texte intégral

Résumé :

Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-acting drug delivery systems/devices to treat chronic eye conditions. This review covers several drug delivery nanocarriers that can control chronic eye disorders non-invasively. However, most of the developed nanocarriers are still in preclinical or clinical stages. Long-acting drug delivery systems,

Styles APA, Harvard, Vancouver, ISO, etc.

16

Doshi, Preeti, Vijay Bhaskar Bandikatla, Krishna Poddar, Rajkumar Arora, Pravesh Kanthed, and Samarjit Dey. "Best Practice Recommendations for Implantable Neuromodulation Therapies for Pain II: Intrathecal Drug Delivery Systems; Peripheral Nerve Stimulation; Sacral Neuromodulation." Indian Journal of Pain 37, no. 3 (2023): 152–63. http://dx.doi.org/10.4103/ijpn.ijpn_71_23.

Texte intégral

Résumé :

This is a part II of the best practice recommendations for implantable neuromodulation therapies for pain. Part I has already covered Spinal cord stimulation (SCS). We shall be be covering Intrathecal drug delivery systems (IDDS), Peripheral nerve stimulation (PNS) and Sacral nerve neuromodulation (SNM) in this article. Chronic pain has a huge global prevalence of 20% and in a country like India which has been labeled by the UN as the most populous country in April 2023, the problem is likely to explode and pose a huge challenge to Indian Practitioners. In addition to this can also be due to a

Styles APA, Harvard, Vancouver, ISO, etc.

17

Smith, T. J., P. J. Coyne, P. S. Staats, et al. "An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)." Annals of Oncology 16, no. 5 (2005): 825–33. http://dx.doi.org/10.1093/annonc/mdi156.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

Smith, Thomas J., and Patrick J. Coyne. "Implantable Drug Delivery Systems (IDDS) After Failure of Comprehensive Medical Management (CMM) Can Palliate Symptoms in the Most Refractory Cancer Pain Patients." Journal of Palliative Medicine 8, no. 4 (2005): 736–42. http://dx.doi.org/10.1089/jpm.2005.8.736.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Neto, Jorge Taqueda. "Intrathecal Drug Delivery System in Chronic Low Back Pain: Case Series." Pain Medicine Case Reports 7, no. 4 (2023): 217–21. http://dx.doi.org/10.36076/pmcr.2023.7.217.

Texte intégral

Résumé :

Background: Modern science says that persistent low back pain is the main cause of years lived in disability. Among pain management approaches, we highlight the intrathecal drug delivery system (IDDS). The aim of this observational study was to assess pain intensity in a series of cases of patients with chronic low back pain using IDDS. Case Series: This is a series of cases with 14 patients affected by chronic degenerative spinal disease using IDDS. Regarding age, an average of 81.57 (SD ± 7.44) was obtained, in addition, everybody reported being retired, having at least completed high school

Styles APA, Harvard, Vancouver, ISO, etc.

20

Goel, Vasudha, Amol M. Patwardhan, Mohab Ibrahim, Hariharan Shankar, and David M. Schultz. "Indented intrathecal drug delivery system with loss of reservoir volume." Regional Anesthesia & Pain Medicine 44, no. 7 (2019): 747–49. http://dx.doi.org/10.1136/rapm-2019-100516.

Texte intégral

Résumé :

ObjectivesWe report two patients who underwent elective revision surgery were found to have reduced reservoir volumes and indented bottom shield of intrathecal drug delivery system (IDDS).Case reportsCase #1: A 59-year-old man stable on IDDS medications for chronic neck and upper back pain was found to have an irreversible reduction in reservoir volume from 40 to 28 cc on routine refill appointment. Despite having stable pain control, the reservoir volume decreased from 40 to 22 cc and subsequently to 17 cc when the patient had inadequate pain control. During replacement surgery, the posterior

Styles APA, Harvard, Vancouver, ISO, etc.

21

Fitzgibbon, Dermot R., Linda S. Stephens, Karen L. Posner, et al. "Injury and Liability Associated with Implantable Devices for Chronic Pain." Anesthesiology 124, no. 6 (2016): 1384–93. http://dx.doi.org/10.1097/aln.0000000000001122.

Texte intégral

Résumé :

Abstract Background Due to an increase in implantable device–related anesthesia pain medicine claims, the authors investigated anesthesia liability associated with these devices. Methods After institutional review board approval, the authors identified 148 pain medicine device claims from 1990 or later in the Anesthesia Closed Claims Project Database. Device-related damaging events included medication administration events, infections, hematomas, retained catheter fragments, cerebrospinal fluid leaks, cord or cauda equina trauma, device placed at wrong level, stimulator incorrectly programmed,

Styles APA, Harvard, Vancouver, ISO, etc.

22

Neuman, Dr Stephanie A. "Post Dural Puncture Headache Following Intrathecal Drug Delivery System Placement." Pain Physician 2;16, no. 2;3 (2013): 101–7. http://dx.doi.org/10.36076/ppj.2013/16/101.

Texte intégral

Résumé :

Background: Placement of an intrathecal drug delivery system (IDDS) may provide substantial benefit to certain patients. However, placement of these devices is not without complications, and minimal data exist describing the rates of these complications. Specifically, there is a paucity of data describing the incidence of post dural puncture headache (PDPH) following IDDS placement. Objectives: The aim of this study was to identify the incidence and treatment course of PDPH following placement of an IDDS in a retrospective review. Study Design: Retrospective assessment of medical records. Sett

Styles APA, Harvard, Vancouver, ISO, etc.

23

Pranav, Shinde* Rekha Goukonde Dr. Gajanan Sanap. "Implantable Drug Delivery System." International Journal of Pharmaceutical Sciences 3, no. 1 (2025): 659–70. https://doi.org/10.5281/zenodo.14628080.

Texte intégral

Résumé :

In this paper, we present a shape-programmable magnetically actuated soft capsule robot for semiim plan table drug delivery applications. The shape of the proposed soft capsule is changed by an external magnetic field. To change the robot shape by an external permanent magnet, the relevant soft robot design features and required conditions are investigated using simulations and experiments. If the magnetic field is increased above a critical value, the capsule collapses to a sphere-like stable shape, which keeps the capsule inside the stomach all the time, and it cannot move to the duodenum by

Styles APA, Harvard, Vancouver, ISO, etc.

24

Upadhyay, Surjya Prasad, and Piyush N. Mallick. "Intrathecal Drug Delivery System (IDDS) for Cancer Pain Management." American Journal of Hospice and Palliative Medicine® 29, no. 5 (2011): 388–98. http://dx.doi.org/10.1177/1049909111426134.

Texte intégral

Résumé :

Cancer pain remains undertreated and a significant number of patients with cancer pain die from severe untreated pain. With increasing survival rate in cancer, the prevalence of cancer pain is also increasing in number. Though majority of patients with cancer pain can be effectively treated with conventional medical management, still a significant portion of patients required some form of interventional pain management techniques. Among the interventional techniques, intrathecal drug delivery is increasingly used in cancer pain management. Our objective of this article is to review literatures

Styles APA, Harvard, Vancouver, ISO, etc.

25

Gebhardt, Rodolfo. "SynchroMed II Intrathecal Pump Memory Errors Due to Repeated Magnetic Resonance Imaging." Pain Physician 6;15, no. 6;12 (2012): 475–77. http://dx.doi.org/10.36076/ppj.2012/15/475.

Texte intégral

Résumé :

Cancer patients with severe refractory pain are often managed with implantable drug delivery systems (IDDS). The only drugs with US Food and Drug Administration approval for intrathecal use are morphine, ziconotide, and baclofen. Other drugs used and mixed include, hydromorphone, bupivacaine, sufentanil, and fentanyl. These patients often undergo magnetic resonance imaging (MRI) for disease-related monitoring and diagnoses. Although uncommon, IDDS can fail to resume normal functioning after MRI, potentially causing complications. The magnetic field of an MRI will temporarily stop the rotor of

Styles APA, Harvard, Vancouver, ISO, etc.

26

Fayzullin, Alexey, Semyon Churbanov, Natalia Ignatieva, et al. "Local Delivery of Pirfenidone by PLA Implants Modifies Foreign Body Reaction and Prevents Fibrosis." Biomedicines 9, no. 8 (2021): 853. http://dx.doi.org/10.3390/biomedicines9080853.

Texte intégral

Résumé :

Peri-implant fibrosis (PIF) increases the postsurgical risks after implantation and limits the efficacy of the implantable drug delivery systems (IDDS). Pirfenidone (PF) is an oral anti-fibrotic drug with a short (<3 h) circulation half-life and strong adverse side effects. In the current study, disk-shaped IDDS prototype combining polylactic acid (PLA) and PF, PLA@PF, with prolonged (~3 days) PF release (in vitro) was prepared. The effects of the PLA@PF implants on PIF were examined in the rabbit ear skin pocket model on postoperative days (POD) 30 and 60. Matching blank PLA implants (PLA0

Styles APA, Harvard, Vancouver, ISO, etc.

27

Mujahidul islam, Mujahidul islam, and dr Hemachandran Ravikumar. "Biodegradable Implantable Drug Delivery System." International Journal of Pharmaceutical Research and Applications 10, no. 3 (2025): 2271–76. https://doi.org/10.35629/4494-100322712276.

Texte intégral

Résumé :

Conventional drug delivery routes are commonly used due to their ease of administration and systemic effects. However, they present significant limitations such as hepatic firstpass metabolism, gastrointestinal degradation, hypersensitivity reactions, low bioavailability, and fluctuating plasma drug levels. These drawbacks reduce patient compliance, especially in chronic therapies. To address these issues, implantable polymeric drug delivery systems offer controlled and sustained drug release from devices implanted in the body. While non-biodegradable implants require surgical removal and show

Styles APA, Harvard, Vancouver, ISO, etc.

28

Atallah, Joseph. "Use of Eptifibatide as a Bridge Antiplatelet Agent for Intrathecal Drug Delivery System Placement." Pain Physician 6;15, no. 6;12 (2012): 479–83. http://dx.doi.org/10.36076/ppj.2012/15/479.

Texte intégral

Résumé :

Use of antiplatelet agents is becoming increasingly common, and their management may require new strategies if neuroaxial techniques are to be employed in patients who will not tolerate discontinuation of antiplatelet therapy. The patient was a 46-year-old man with a past medical history significant for coronary artery disease and who had undergone 14 stents. He developed stent thrombosis (ST) while on clopidogrel. Following the ST, he was subsequently placed on prasugrel. While on prasugrel, the patient presented for an intrathecal drug delivery system (IDDS) trial and placement due to severe

Styles APA, Harvard, Vancouver, ISO, etc.

29

Ding, Yongyong, Hong Deng, and Jie Peng. "Clinical observation of the treatment of refractory cancer pain with cancer pain information platform and IDDS under home analgesia mode: A retrospective study." Medicine 103, no. 27 (2024): e38765. http://dx.doi.org/10.1097/md.0000000000038765.

Texte intégral

Résumé :

To evaluate the effectiveness and safety of a cancer pain information platform combined with semi-implantable intrathecal drug delivery systems among the patients with refractory cancer pain under a “home analgesia” model. This was a retrospective study. A total of 49 patients underwent semi-implantable intrathecal drug delivery systems with patient-controlled analgesia in conjunction with the establishment of a cancer pain information platform. Numeric rating scales (NRS), Bruggrmann comfort scale (BCS), high-quality sleep duration, and opioid-related adverse effects were recorded at various

Styles APA, Harvard, Vancouver, ISO, etc.

30

Wang, Shen Guo, Qing Cai, Jian Zhong Bei, Wei Yun Shi, and Li Xin Xie. "An Implantable Immunosuppressive Cyclosporine Drug Delivery System." Key Engineering Materials 288-289 (June 2005): 125–28. http://dx.doi.org/10.4028/www.scientific.net/kem.288-289.125.

Texte intégral

Résumé :

In the article a kind biodegradable drug carrier (glycolide-co-lactide-co-caprolactone) tricomponent copolymer (PGLC) was synthesized by ring opening copolymerization of glycolide (GA), lactide (LA) and ε-caprolactone (CL), and was used to manufacture an implantable drug preparation---Cyclosporine-PGLC drug delivery system (Cs-PGLC DDS).The Cs could slowly release from the Cs-PGLC DDS near linearly and last for a long time in vitro. A clinically significant Cs concentration in the cornea and anterior chamber could be achieved by implanting the Cs-PGLC DDS in anterior chamber. It was demonstrat

Styles APA, Harvard, Vancouver, ISO, etc.

31

Beckham, W. A. "Irradiation involving an implantable drug delivery system." Radiotherapy and Oncology 42, no. 1 (1997): 92–93. http://dx.doi.org/10.1016/s0167-8140(96)01863-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Glicksman, Michael. "Spinal Cord Stimulation and Intrathecal Drug Delivery System Therapy in a Pregnant Patient with Complex Regional Pain Syndrome Type II: A Case Report." Pain Medicine Case Reports 8, no. 3 (2024): 81–90. http://dx.doi.org/10.36076/pmcr.2024.8.81.

Texte intégral

Résumé :

BACKGROUND: Complex Regional Pain Syndrome (CRPS) is a difficult-to-treat chronic pain condition. When indicated, spinal cord stimulator (SCS) therapy can serve as a solution. Rarely, intrathecal drug delivery system (IDDS) can be used with SCS to enhance analgesia. Given women’s predisposition towards CRPS, there may be an increasing co-existence of pregnancy and CRPS. CASE REPORT: A pregnant woman presented with right lower extremity pain due to CRPS type II. Here, we present the first case of a woman who continued SCS and IDDS therapies throughout pregnancy. She had an uncomplicated pregnan

Styles APA, Harvard, Vancouver, ISO, etc.

33

Bendel, Markus A., Susan M. Moeschler, Wenchun Qu, et al. "Treatment of Refractory Postdural Puncture Headache after Intrathecal Drug Delivery System Implantation with Epidural Blood Patch Procedures: A 20-Year Experience." Pain Research and Treatment 2016 (August 11, 2016): 1–5. http://dx.doi.org/10.1155/2016/2134959.

Texte intégral

Résumé :

A recent publication reported the incidence of postdural puncture headache (PDPH) in conjunction with intrathecal drug delivery system (IDDS) implantation to be nearly 23 percent. Many patients responded to conservative measures but a percentage needed invasive treatment with an epidural blood patch (EBP). There is limited data to describe the technical details, success rates, and complications associated with EBP in this population. This study aims to provide a retrospective report of EBP for patients suffering from PDPH related to IDDS implantation. A chart review established a cohort of pat

Styles APA, Harvard, Vancouver, ISO, etc.

34

Sutradhar, Kumar Bishwajit, and Chandra Datta Sumi. "Implantable microchip: the futuristic controlled drug delivery system." Drug Delivery 23, no. 1 (2014): 1–11. http://dx.doi.org/10.3109/10717544.2014.903579.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

Lee, Meng-Shiue, Da-Jeng Yao, and Wensyang Hsu. "An Implantable Drug-delivery System on a Chip." Current Topics in Medicinal Chemistry 15, no. 15 (2015): 1516–24. http://dx.doi.org/10.2174/1568026615666150414121427.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

Lopez, A. J., P. S. Sidhu, D. Dutka, and C. Cousins. "Radiological insertion of an implantable drug delivery system." British Journal of Radiology 67, no. 797 (1994): 491–93. http://dx.doi.org/10.1259/0007-1285-67-797-491.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Abjel, A.* Gopi S. Sukesh Kumar. "Smart Drug Delivery System." International Journal in Pharmaceutical Sciences 1, no. 10 (2023): 31–43. https://doi.org/10.5281/zenodo.8418711.

Texte intégral

Résumé :

SDDS is a medicine delivery strategy that attempts to increase dosage in specific body areas while increasing therapeutic efficacy and decreasing adverse effects. It addresses issues such as pharmaceutical solubility constraints, degradation, quick clearance rates, non-specific toxicity, and biological barriers. Smart drug delivery methods include nanoparticles, liposomes, vesicles, implants, polymer-based systems, PH-responsive systems, nanoplatforms, and tailored systems. Nanoparticles contain organic and inorganic features, whereas liposomes are used in cancer therapy, anti-inflammatory the

Styles APA, Harvard, Vancouver, ISO, etc.

38

Hoekstra, A. "Pain Relief Mediated by Implantable Drug Delivery Devices." International Journal of Artificial Organs 17, no. 3 (1994): 151–54. http://dx.doi.org/10.1177/039139889401700305.

Texte intégral

Résumé :

Various totally implantable drug delivery systems from single access ports to micropumps are now available for administration of repeated boluses, and continuous or programmable infusions. In this respect, emphasis is given to a relatively cheap, totally implantable system for self-administering intraspinal opiates in the treatment of cancer pain. The SECOR® pump system, developed by Cordis, consists of a dual pump with refill port and safety valve. The volume of the pliable reservoir is 12 ml and refill is accomplished with a 25-G needle. The bolus delivered with each transcutaneous activatio

Styles APA, Harvard, Vancouver, ISO, etc.

39

Dupoiron, Denis, Damien Leblanc, Sybille Demelliez-Merceron, et al. "Optimizing Initial Intrathecal Drug Ratio for Refractory Cancer-Related Pain for Early Pain Relief. A Retrospective Monocentric Study." Pain Medicine 20, no. 10 (2019): 2033–42. http://dx.doi.org/10.1093/pm/pnz096.

Texte intégral

Résumé :

Abstract Objective Intrathecal (IT) drug delivery has shown its efficiency in treating refractory cancer pain, but switching opioids from the systemic to the intrathecal route is a challenging phase. Moreover, associations are widely used and recommended. Few data deal with the initial dosage of each drug. Analyzing conversion factors and initial dosages used in intrathecal therapy seems essential to decreasing the length of titration and to delivering quick pain relief to patients. Methods We retrospectively analyzed data from consecutive adult patients implanted with an intrathecal device fo

Styles APA, Harvard, Vancouver, ISO, etc.

40

Amina, Nalongo J. "Engineering Solutions for Drug Delivery System." Research Output Journal of Biological and Applied Science 4, no. 3 (2024): 47–50. http://dx.doi.org/10.59298/rojbas/2024/434750.

Texte intégral

Résumé :

This paper examines the evolution of engineering solutions in drug delivery systems, emphasizing the role of nanotechnology in overcoming current challenges in precision medicine. It addresses key challenges in drug delivery, including targeting specificity, minimizing adverse effects, and enhancing the efficiency of drug carriers. Both top-down and bottom-up engineering approaches are examined, with case studies highlighting successful applications in cancer therapy, gene delivery, and implantable devices. The paper also investigates future trends, such as smart and active delivery systems, a

Styles APA, Harvard, Vancouver, ISO, etc.

41

Koutsamanis, Ioannis, Martin Spoerk, Florian Arbeiter, Simone Eder, and Eva Roblegg. "Development of Porous Polyurethane Implants Manufactured via Hot-Melt Extrusion." Polymers 12, no. 12 (2020): 2950. http://dx.doi.org/10.3390/polym12122950.

Texte intégral

Résumé :

Implantable drug delivery systems (IDDSs) offer good patient compliance and allow the controlled delivery of drugs over prolonged times. However, their application is limited due to the scarce material selection and the limited technological possibilities to achieve extended drug release. Porous structures are an alternative strategy that can overcome these shortcomings. The present work focuses on the development of porous IDDS based on hydrophilic (HPL) and hydrophobic (HPB) polyurethanes and chemical pore formers (PFs) manufactured by hot-melt extrusion. Different PF types and concentration

Styles APA, Harvard, Vancouver, ISO, etc.

42

Yi, Ying, Ulrich Buttner, and Ian G. Foulds. "A cyclically actuated electrolytic drug delivery device." Lab on a Chip 15, no. 17 (2015): 3540–48. http://dx.doi.org/10.1039/c5lc00703h.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

43

Stewart, Sarah, Juan Domínguez-Robles, Ryan Donnelly, and Eneko Larrañeta. "Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications." Polymers 10, no. 12 (2018): 1379. http://dx.doi.org/10.3390/polym10121379.

Texte intégral

Résumé :

The oral route is a popular and convenient means of drug delivery. However, despite its advantages, it also has challenges. Many drugs are not suitable for oral delivery due to: first pass metabolism; less than ideal properties; and side-effects of treatment. Additionally, oral delivery relies heavily on patient compliance. Implantable drug delivery devices are an alternative system that can achieve effective delivery with lower drug concentrations, and as a result, minimise side-effects whilst increasing patient compliance. This article gives an overview of classification of these drug delive

Styles APA, Harvard, Vancouver, ISO, etc.

44

Davis, Mellar P., Declan Walsh, Ruth Lagman, and Susan B. LeGrand. "Randomized Clinical Trial of an Implantable Drug Delivery System." Journal of Clinical Oncology 21, no. 14 (2003): 2800–2801. http://dx.doi.org/10.1200/jco.2003.99.003.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

45

Shivkanya, Jadhav* Amol Supekar Kanchan Jawale Aarti Garje Vaishnavi Jaygude Sanika Sarode Amol Supekar. "Novel Drug Delivery System: Exploring advancements in drug delivery systems such as Nanoparticles, Lyposome and Implantable devices." International Journal of Pharmaceutical Sciences 3, no. 2 (2025): 1569–81. https://doi.org/10.5281/zenodo.14889397.

Texte intégral

Résumé :

Over the past few decades, there has been significant research interest in drug delivery systems employing particulate carriers for molecules of varying sizes. Particulate systems, such as nanoparticles and liposomes, have been utilized to enhance the pharmacokinetic and pharmacodynamic properties of drugs. They function in vivo to shield drugs in circulation, regulate access to target sites, and enable controlled, sustained release at the site of action. Various polymers have been employed in nanoparticle formulations to optimize therapeutic efficacy while minimizing side effects. Liposomes,

Styles APA, Harvard, Vancouver, ISO, etc.

46

Manickavasagam, Dharani, and Moses O. Oyewumi. "Critical Assessment of Implantable Drug Delivery Devices in Glaucoma Management." Journal of Drug Delivery 2013 (August 26, 2013): 1–12. http://dx.doi.org/10.1155/2013/895013.

Texte intégral

Résumé :

Glaucoma is a group of heterogeneous disorders involving progressive optic neuropathy that can culminate into visual impairment and irreversible blindness. Effective therapeutic interventions must address underlying vulnerability of retinal ganglion cells (RGCs) to degeneration in conjunction with correcting other associated risk factors (such as elevated intraocular pressure). However, realization of therapeutic outcomes is heavily dependent on suitable delivery system that can overcome myriads of anatomical and physiological barriers to intraocular drug delivery. Development of clinically vi

Styles APA, Harvard, Vancouver, ISO, etc.

47

Shaikh, Sahil, Rohit Satpute,, Ankita Satpute, Shelke Omkar, and Mr Vijay Pawar. "“A Perceptive Review on Advancement in Drug Delivery System”." International Journal of Pharmaceutical Research and Applications 09, no. 05 (2024): 495–504. https://doi.org/10.35629/4494-0905495504.

Texte intégral

Résumé :

Drug targeting to specific organs and tissues has become one of the critical endeavors of the century since the use of free drugs in conventional dosage forms generally involves difficulties in achieving the target site at the appropriate dose after or during a proper time period. Recent drug delivery systems (DDS) are formulated using advanced technology to accelerate systemic drug delivery to the specific target site, maximizing therapeutic efficacy and minimizing off-target accumulation in the body. As a result, they play an important role in disease management and treatment. This review ex

Styles APA, Harvard, Vancouver, ISO, etc.

48

KONING, GERRIT, and FREDERICK FEITH. "A New Implantable Drug Delivery System for Patient-Controlled Analgesia." Annals of the New York Academy of Sciences 531, no. 1 Neurological (1988): 48–56. http://dx.doi.org/10.1111/j.1749-6632.1988.tb31811.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

49

Compoginis, John M., Steven H. Richeimer, and Garry S. Brody. "Placement of an Implantable Drug Delivery System Under the Breast." Pain Medicine 8, no. 6 (2007): 521–24. http://dx.doi.org/10.1111/j.1526-4637.2006.00286.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Yang, Rongbing, Alexander V. Gorelov, Fawaz Aldabbagh, William M. Carroll, and Yury Rochev. "An implantable thermoresponsive drug delivery system based on Peltier device." International Journal of Pharmaceutics 447, no. 1-2 (2013): 109–14. http://dx.doi.org/10.1016/j.ijpharm.2013.02.051.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!